FDA reviewing new use for migraine medication developed in New Haven

New Haven

NEW HAVEN, Conn. (WTNH) — The Food and Drug Administration (FDA) will review a new use for a migraine medication developed by Biohaven, based in New Haven.

RELATED: New Haven-based pharmaceutical company releases new migraine meds as many experience pandemic stress

Nurtec has already been approved to provide pain relief for people suffering from migraines. Now, the FDA will review if it can be used to prevent them.

The company is also in phase 2 of trying one of its other drugs on COVID-19 survivors with lung damage.

Copyright 2020 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

New Haven

M.O.V.E. -- West Haven mom dedicates life to helping those affected by domestic violence

News /

United Way of Milford serving more local families amid pandemic

News /

Walks with Buddy joins Gil on the Go

News /

Tallest flagpole in CT is on Milford Green

News /

44-year-old woman shot, killed in New Haven apartment, death ruled homicide

News /

'Listen to your grandmother': Naugatuck grandmas use social media to try and save Halloween

News /
More New Haven

Trending Stories

Don't Miss

More Don't Miss